Autobio Diagnostics Co

Autobio Diagnostics Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Autobio Diagnostics Co (603658.SS) as of Oct 19, 2026 is 0.20. In the previous year, Total Debt to EBITDA Ratio was 0.25 — a change of -20.09% (lower).

Debt/EBITDA

0.20

YoY

-20.09%

Last updated:

Total Debt to EBITDA Ratio of Autobio Diagnostics Co is 2024 0.20 . Total Debt to EBITDA Ratio of Autobio Diagnostics Co was 2023 0.25 . It decreases by -20.09% lower compared to the previous year.

The Autobio Diagnostics Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.08 CNY
Jan 1, 2018
0.14 CNY
Jan 1, 2019
0.82 CNY
Jan 1, 2020
0.21 CNY
Jan 1, 2021
0.20 CNY
Jan 1, 2022
0.09 CNY
Jan 1, 2023
0.25 CNY
Jan 1, 2024
0.20 CNY
The Autobio Diagnostics Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.20-20.09%
0.25+164.64%
0.09-53.22%
0.20-6.06%
0.21-74.20%
0.82+474.45%
0.14+85.23%
0.08-74.69%
0.30+115.10%
0.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co Ltd, listed on the Shanghai Stock Exchange under ticker 603658.SS, is a healthcare company based in Zhengzhou, China. The company specializes in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. With a workforce of 5,505 employees, Autobio Diagnostics went public on September 1, 2016. Its product portfolio includes immunodiagnostic reagents such as microplate chemiluminescence diagnostic reagents, enzyme-linked immunosorbent assay (ELISA) diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The company also offers microbiology detection products, including training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products encompass microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. Autobio Diagnostics primarily serves domestic markets within China, focusing on providing diagnostic solutions for healthcare applications. The company's headquarters is located in Zhengzhou, Henan Province, and it operates within the healthcare sector, specifically in the health care industry. Its website, https://www.autobio.com.cn/, provides further information on its services and products. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Total Debt to EBITDA Ratio of Autobio Diagnostics Co is 0.20 in 2024.

Total Debt to EBITDA Ratio of Autobio Diagnostics Co changed from 0.25 to 0.20, representing a -20.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Autobio Diagnostics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Autobio Diagnostics Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Autobio Diagnostics Co